Revenue (Tables)

6 Months Ended

Jun. 30, 2019

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

The following table summarizes our revenue recognized in our consolidated condensed statements of operations:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Net product revenue	$	5,168.7	$	5,129.4	$	9,861.0	$	9,735.3
Collaboration and other revenue (1)	468.0		455.6		867.9		813.5
Revenue	$	5,636.7	$	5,585.0	$	10,728.9	$	10,548.8

⁽¹⁾ Collaboration and other revenue associated with prior period transfers of intellectual property was $59.6 million and $95.1 million during the three and six months ended June 30, 2019, respectively, and $133.6 million and $183.7 million during the three and six months ended June 30, 2018, respectivel

The following table summarizes revenue by product:

	Three Months Ended June 30,
	2019						2018
	United States (U.S.) (1)		Outside U.S.		Total		U.S. (1)		Outside U.S.		Total
Revenue—to unaffiliated customers:
Endocrinology:
Trulicity®	$	792.1	$	236.4	$	1,028.5	$	612.4	$	167.4	$	779.8
Humalog® (2)	396.1		281.5		677.6		464.5		305.2		769.8
Forteo®	172.8		188.0		360.8		225.1		209.4		434.5
Humulin®	220.1		102.6		322.6		238.8		107.2		346.0
Basaglar®	232.2		58.6		290.7		156.5		45.3		201.8
Jardiance (3)	142.6		89.3		231.9		85.6		61.6		147.2
Trajenta (4)	64.5		89.5		153.9		56.8		84.9		141.7
Other Endocrinology	81.6		59.3		141.2		61.5		72.8		134.1
Total Endocrinology	2,102.0		1,105.2		3,207.2		1,901.2		1,053.8		2,954.9
Oncology:
Alimta®	341.7		236.1		577.8		281.3		274.6		555.9
Cyramza®	89.8		152.0		241.8		75.4		143.3		218.8
Erbitux®	136.9		22.4		159.3		140.0		26.4		166.4
Verzenio®	105.2		28.7		133.9		57.7		—		57.7
Other Oncology	16.2		68.2		84.4		56.7		54.7		111.3
Total Oncology	689.8		507.4		1,197.2		611.1		499.0		1,110.1
Neuroscience:
Cymbalta®	18.1		169.0		187.2		12.6		169.4		181.9
Zyprexa®	9.3		95.1		104.3		11.8		116.2		128.0
Strattera®	21.2		61.4		82.6		16.9		97.3		114.2
Emgality®	33.8		0.5		34.3		—		—		—
Other Neuroscience	22.0		22.3		44.3		24.3		22.4		46.9
Total Neuroscience	104.4		348.3		452.7		65.6		405.3		471.0
Immunology:
Taltz®	268.1		85.7		353.8		173.6		46.5		220.1
Olumiant®	10.7		91.7		102.4		1.7		42.9		44.7
Total Immunology	278.8		177.3		456.1		175.3		89.4		264.7
Other:
Cialis®	35.1		165.1		200.2		345.7		193.0		538.7
Other	42.4		80.8		123.3		143.4		102.2		245.6
Total Other	77.5		245.9		323.5		489.1		295.2		784.3
Revenue	$	3,252.5	$	2,384.2	$	5,636.7	$	3,242.3	$	2,342.7	$	5,585.0

Numbers may not add due to rounding.

⁽¹⁾ U.S. revenue includes revenue in Puerto Rico.

⁽²⁾ Humalog revenue includes Insulin Lispro.

⁽³⁾ Jardiance revenue includes Glyxambi^® and Synjardy^®.

⁽⁴⁾ Trajenta revenue includes Jentadueto^®.

	Six Months Ended June 30,
	2019						2018
	U.S. (1)		Outside U.S.		Total		U.S. (1)		Outside U.S.		Total
Revenue—to unaffiliated customers:
Endocrinology:
Trulicity	$	1,457.7	$	450.6	$	1,908.3	$	1,140.6	$	317.5	$	1,458.1
Humalog (2)	844.8		563.7		1,408.4		968.7		592.8		1,561.5
Forteo	298.7		375.0		673.7		347.2		400.5		747.8
Humulin	421.3		199.0		620.3		460.4		211.5		671.9
Basaglar	430.3		111.8		542.1		283.2		84.6		367.8
Jardiance (3)	267.8		167.7		435.5		180.6		117.6		298.2
Trajenta (4)	111.8		174.0		285.9		110.9		171.9		282.8
Other Endocrinology	143.5		119.6		263.1		125.4		140.2		265.6
Total Endocrinology	3,975.9		2,161.4		6,137.3		3,617.0		2,036.6		5,653.7
Oncology:
Alimta	623.5		453.5		1,076.9		526.7		528.9		1,055.5
Cyramza	164.9		275.2		440.0		143.7		258.7		402.4
Erbitux	250.3		27.5		277.7		261.3		54.7		316.1
Verzenio	198.7		44.6		243.3		87.4		—		87.4
Other Oncology	46.3		125.5		172.1		102.3		103.0		205.3
Total Oncology	1,283.7		926.3		2,210.0		1,121.4		945.3		2,066.7
Neuroscience:
Cymbalta	28.4		322.9		351.3		24.8		326.7		351.5
Zyprexa	18.6		193.0		211.5		20.6		230.0		250.6
Strattera	22.7		126.1		148.8		63.9		181.0		244.9
Emgality	46.0		2.6		48.5		—		—		—
Other Neuroscience	39.8		45.7		85.8		48.5		48.2		96.7
Total Neuroscience	155.5		690.3		845.9		157.8		785.9		943.7
Immunology:
Taltz	449.0		157.4		606.3		284.7		81.8		366.5
Olumiant	17.1		167.4		184.5		1.7		75.2		76.9
Total Immunology	466.0		324.8		790.8		286.5		157.0		443.4
Other:
Cialis	178.4		330.0		508.4		659.1		375.0		1,034.1
Other	83.8		152.8		236.5		196.1		211.1		407.2
Total Other	262.2		482.9		744.9		855.2		586.1		1,441.3
Revenue	$	6,143.3	$	4,585.6	$	10,728.9	$	6,037.9	$	4,510.9	$	10,548.8

Numbers may not add due to rounding.

⁽¹⁾ U.S. revenue includes revenue in Puerto Rico.

⁽²⁾ Humalog revenue includes Insulin Lispro.

⁽³⁾ Jardiance revenue includes Glyxambi and Synjardy.

⁽⁴⁾ Trajenta revenue includes Jentadueto.

The following table summarizes revenue by geographical area:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Revenue—to unaffiliated customers (1):
United States (2)	$	3,252.5	$	3,242.3	$	6,143.3	$	6,037.9
Europe	928.2		941.0		1,828.5		1,834.8
Japan	653.2		640.4		1,196.9		1,177.2
Other foreign countries	802.8		761.2		1,560.2		1,498.8
Revenue	$	5,636.7	$	5,585.0	$	10,728.9	$	10,548.8

Numbers may not add due to rounding.

⁽¹⁾ Revenue is attributed to the countries based on the location of the customer.

⁽²⁾ U.S. revenue includes revenue in Puerto Rico.

Schedule of amounts recorded for contract liabilities

The following table summarizes contract liability balances:

	June 30, 2019		December 31, 2018
Contract liabilities	$	277.6	$	294.9